Tanios S. Bekaii-Saab, MD, Mayo Clinic

Evolutions in the HER2-Amplified CRC Treatment Landscape

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 28th 2023

Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.

Real-World Use of HER2-Directed Therapies in Colorectal Cancers

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 28th 2023

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

HER2-Amplified Colorectal Cancer: Clinical Trial Data

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 21st 2023

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

Treatment Algorithm for Metastatic Colorectal Cancer

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 21st 2023

Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.

Role of Circulating Tumor DNA Testing in Colorectal Cancer

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 14th 2023

In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.

Role of HER2 Expression in Colorectal Cancer

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, Vanderbilt University,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 14th 2023

A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.

Colorectal Cancer: An Overview on Molecular Profiling

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 7th 2023

Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.

Colorectal Cancer: Prevalence, Workup, and Molecular Subtypes

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Pashtoon M. Kasi, MD, MBBS, MS,Aparna R. Parikh, MD

April 7th 2023

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.

Future Directions for mCRC Management

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

January 27th 2022

Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.

Sequencing Therapy for Relapsed mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

January 27th 2022

Gerald Prager, MD, leads the discussion on sequencing strategies for patients with relapsed mCRC, including those not previously treated with anti-EGFR inhibitors.

Management of Relapsed mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

January 27th 2022

Gerald Prager, MD, and Chiara Cremolini, MD, PhD, share their approach to managing the case of a 72-year-old man with mCRC disease progression and provide insight on rechallenging patients with anti-EGFR regimens.

Dosing Strategies for Regorafenib for Patients With mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

January 27th 2022

Chiara Cremolini, MD, PhD, discusses dosing strategies and the optimal management of adverse events with regorafenib for patients with mCRC.

Treatment Options After Progression on Chemotherapy/Anti-EGFR Therapy for mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

January 27th 2022

Experts in gastrointestinal cancers explore treatment approaches, such as with regorafenib, in patients with mCRC who have progressed on chemotherapy/anti-EGFR therapy.

Role of Maintenance Therapy in Advanced CRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

January 27th 2022

Chiara Cremolini, MD, PhD; Gerald Prager, MD; and Tanios S. Bekaii-Saab, MD, share their approach to maintenance therapy, including with EGFR inhibitors, for the management of advanced CRC.

Using ICI Therapy in MSI-High mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

January 27th 2022

Chiara Cremolini, MD, PhD, leads the discussion on the advantage of treating MSI-high metastatic colorectal cancer with immune checkpoint inhibitors.

Selecting Frontline Therapy for Newly Diagnosed mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

January 27th 2022

Tanios S. Bekaii-Saab, MD, presents the case of a 65-year-old woman with stage IV adenocarcinoma of the rectum, and the panel reviews frontline treatment options for a patient with newly diagnosed mCRC.

Role of Genomic Testing in mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

November 30th 2021

Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.

Overview of Colorectal Cancer

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Chiara Cremolini, MD, PhD, University of Pisa,Gerald Prager, MD, Medical University of Vienna

November 30th 2021

Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.

Treatments for BRAF-Mutated mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 16th 2021

Considerations for treating BRAF-mutated metastatic colorectal cancer with the combination of a BRAF inhibitor plus anti-EGFR agent based on recently presented data.

Second-Line Treatment of mCRC: Rechallenging Therapy

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, The University of Texas MD Anderson Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 16th 2021

The role of molecular assays, including liquid biopsies, in providing information on resistance mechanisms in metastatic colorectal cancer and the impact of testing results on decisions for rechallenging with a previous therapy.

Preferences for Second-Line Therapy for mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 9th 2021

Drs Cathy Eng and Joleen M. Hubbard explain how patients with metastatic colon cancer typically respond to initial treatment and describe the factors that impact second-line treatment decisions.

Maintenance Therapy for Metastatic CRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

April 9th 2021

Recommendations regarding the selection, initiation, and length of maintenance therapy to help manage cases of metastatic colon cancer.

Optimizing mCRC Treatment: Decision-Making With Patients

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

March 25th 2021

An overview of topics that oncologists should counsel patients on when working with them to select therapy to treat metastatic colon cancer.

Initial Strategies for Assessing and Treating mCRC

ByTanios S. Bekaii-Saab, MD, Mayo Clinic,Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center,Joleen Hubbard, MD, Mayo Clinic,Kanwal Raghav, MD, MBBS, The University of Texas MD Anderson Cancer Center,John H. Strickler, MD, Duke Cancer Institute

March 25th 2021

Experts in gastrointestinal oncology highlight their approaches to assessing patients with newly diagnosed metastatic colorectal cancer and explain the variables that factor into first-line treatment decisions.